Virtual Library

P2.02-001 - Detection of Gene Fusions in NSCLC Using NGS Fusion Assay

09:30 - 09:30  |  Presenter: Yoon-La Choi

P2.02-002 - Digital Multiplexed Detection of Single Nucleotide Variants (SNV) in Non-Small Cell Lung Cancer Using NanoString Technology

09:30 - 09:30  |  Presenter: Brielle Parris

P2.02-003 - A Practical Prognostic lncRNA Signature for Lung Squamous Cell Carcinoma

09:30 - 09:30  |  Presenter: Xiaoshun Shi

P2.02-004 - Gene Mutational Feature in Lung Enteric Adenocarcinoma by the Next Generation Sequencing

09:30 - 09:30  |  Author(s): W. Wang

P2.02-005 - 13 Cases of Molecular Features Analysis in Pulmonary Mucoepidermoid Carcinoma

09:30 - 09:30  |  Author(s): Chunwei Xu

P2.02-006 - NovoSV: Identify and Parse the Pattern of Chromosomal Structural Variation

09:30 - 09:30  |  Author(s): Chunwei Xu

P2.02-007 - Molecular Spectrum of STK11 Gene Mutations in Patients with Non-Small-Cell Lung Cancer in Chinese Patients

09:30 - 09:30  |  Author(s): X. Chen

P2.02-008 - Snai1-Expression Cancer-Associated Fibroblast Induce Epithelial-Mesenchymal Transition of Lungcancer Cells through miR-33b

09:30 - 09:30  |  Author(s): J. You

P2.02-009 - Metabolomic Analysis in Lung Cancer

09:30 - 09:30  |  Presenter: Naohiro Kajiwara

P2.02-010 - Oncogenic Role of PKP1 in Non-Small-Cell Lung Cancer.

09:30 - 09:30  |  Author(s): J. Martin-Padron

P2.02-011 - Clinical and Molecular Features of Lung Cancers with Increased FGFR1 mRNA and/or Gene Copy Number

09:30 - 09:30  |  Presenter: Terry L. Ng

P2.02-012 - The Epigenetic Role of LSD1+8a in Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Aditya Wirawan

P2.02-013 - Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multiregion Exome and TCR Sequencing

09:30 - 09:30  |  Author(s): X. Hu

P2.02-014 - Simultaneous Gene Profiling of Advanced NSCLC: Single-Molecule Quantification of DNA and RNA by nCounter3D™ Technology

09:30 - 09:30  |  Presenter: Cristina Teixidó

P2.02-015 - Mutation Patterns in a Swedish Non-Small Cell Lung Cancer Cohort

09:30 - 09:30  |  Presenter: Linnea La Fleur

P2.02-016 - Pulmonary Sarcomas: A Comprehensive Genomic Profiling Study

09:30 - 09:30  |  Presenter: Jeffrey S. Ross

P2.02-017 - Aberrant Expression of Long Non-Coding RNAs from Pseudogene Loci Highlights Alternative Mechanisms of Cancer Gene Regulation

09:30 - 09:30  |  Presenter: Greg L. Stewart

P2.02-018 - Genomic Profiling of Driver Gene Mutations in 498 Chinese NSCLC Patients

09:30 - 09:30  |  Presenter: Minghui Wang

P2.02-019 - Utility of Circulating Tumor DNA (CtDNA) in Prognostication of Lung Cancer vs. Other Cancer Types

09:30 - 09:30  |  Presenter: Francisco III Maramara Heralde

P2.02-020 - Molecular Characteristics of Patients with PTEN Mutations in Chinese Non-Small Cell Lung Cancer

09:30 - 09:30  |  Author(s): Xiaobing Zheng

P2.02-021 - Prevalence of PTPRD Gene Mutations in Chinese Non-Small Cell Lung Cancer Patients

09:30 - 09:30  |  Author(s): S. Wang

P2.02-022 - Alternative Regulation of Cancer-Associated Genes through Modulation of Long Non-Coding RNAs

09:30 - 09:30  |  Presenter: Adam Patrick Sage

P2.02-023 - Targeted Gene Expression Profiling to Evaluate Minimal Diagnostic FFPE-Biopsies from NSCLC-Patients

09:30 - 09:30  |  Presenter: Johanna Sofia Margareta Mattsson

P2.02-024 - False Positivity Due to Polysomy in Fluorescence in Situ Hybridization

09:30 - 09:30  |  Author(s): A.L. Görtz

P2.02-025 - Histological Difference of Tumor-Infiltrate Lymphocytes in Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Naohiro Kobayashi

P2.02-026 - Impact of PD-L1 Expression on 18F-FDG-PET in Pulmonary Squamous Cell Carcinoma

09:30 - 09:30  |  Presenter: Norimitsu Kasahara

P2.02-027 - Are Inflammatory Markers Predictive of Nivolumab Efficacy in Advanced Non-Small-Cell Lung Cancer (NSCLC)?

09:30 - 09:30  |  Author(s): J. Rogado

P2.02-028 - Prognostic Value of Cox-2 Expression Differs Depending on CD8+ T Lymphocytes and PD-L1 Expression in Resected Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Katsuhiko Shimizu

P2.02-029 - Morphologic Features of Lung Adenocarcinoma Expressing PD-L1 Protein in Small Biopsy Specimens

09:30 - 09:30  |  Presenter: Eun Su Park

P2.02-030 - Bavituximab in Combination With Nivolumab Enhances Tumor Immune Response in a 3D Ex Vivo System of Lung Cancer Patients

09:30 - 09:30  |  Author(s): M. Mediavilla-Varela

P2.02-031 - Relationship between PD-L1 Expression and EGFR/HER2 Signaling in Non-Small-Cell Lung Cancer

09:30 - 09:30  |  Presenter: Riki Okita

P2.02-032 - Interplaying between Gamma-H2AX and Autophagy in A549 Cells Treated with Cisplatin and Etoposide

09:30 - 09:30  |  Presenter: Jong Wook Shin

P2.02-033 - The Association of PD-L1 Expression with Clinical Characteristics and EGFR and ALK Status in Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Jinghui Wang

P2.02-034 - PD-L1 Expression Can Be a Prognostic Marker in EGFR Mutant NSCLC Patients Treated with Erlotinib

09:30 - 09:30  |  Presenter: Niki Karachaliou

P2.02-035 - PD-L1 IHC Test on Cytological Cell Block Specimen; Potential Utility and Practical Issues

09:30 - 09:30  |  Presenter: Michiko Sugiyama

P2.02-036 - The Expression Pattern of CD26/DPP4 in Human Lung Cancer

09:30 - 09:30  |  Author(s): J. Jang

P2.02-037 - CD14⁺ Cell Tumor Microenvironment Infiltration Correlates with Poor Overall Survival in Patients with Early Stage Lung Cancer

09:30 - 09:30  |  Presenter: Erin Schenk

P2.02-038 - Imaging Platform for the Quantification of Cell-Cell Spatial Organization within the Tumour-Immune Microenvironment

09:30 - 09:30  |  Presenter: Katey S.S. Enfield

P2.02-039 - Spatial Heterogeneity of Immunological Markers Between Cores and Complete NSCLC Sections Using Multispectral Fluorescent IHC

09:30 - 09:30  |  Presenter: Geoffrey Peters

P2.02-040 - Cytology Cell Block Is Suitable for Immunohistochemical Testing for PD-L1 in Lung Cancer

09:30 - 09:30  |  Presenter: Hangjun Wang

P2.02-041 - Update on Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer (ICON Project)

09:30 - 09:30  |  Presenter: Jianjun Zhang

P2.02-042 - Clinical Significance of the Tumor Expression of PD-L1 Using Four Immunohistochemistry Assays in Non-Small Cell Lung Cancer. Multicentre Study

09:30 - 09:30  |  Presenter: Cristian Ortiz -Villalón

P2.02-043 - Multicentre Assessment of PD-L1 Immunohistochemistry: Challenges for Establishing the Concordance Between Four Different Antibodies

09:30 - 09:30  |  Presenter: Cristian Ortiz -Villalón

P2.02-044 - Pulmonary Findings in 7 Autopsy Cases of Patients Treated with Immune Checkpoint Inhibitors

09:30 - 09:30  |  Author(s): E.D. Thompson

P2.02-045 - PD-L1 Assessment in Cytology Samples

09:30 - 09:30  |  Author(s): A. Lerner

P2.02-046 - Assessment of PDL1 and Immunoprofiling Using Multiplex Quantitative Immunofluorescence in Lung Cancer: Clinical Implications

09:30 - 09:30  |  Author(s): Tabatha Gutierrez Prieto

P2.02-047 - Comparison of PD-L1 Immunohistochemistry Assays and Response to PD-L1 Inhibitors

09:30 - 09:30  |  Presenter: Sanja Dacic

P2.02-048 - Survival Correlation Between TP53 Gene and PD-L1 Tumour Expression in Resected Non-Small Cell Lung Carcinoma

09:30 - 09:30  |  Presenter: Jane Sze Yin Sui

P2.02-049 - Immunohistochemical Approach in Predicting Primary Lung Cancer Outcome: A Single Center Study

09:30 - 09:30  |  Presenter: Gulrukh Komiljonovna Botiralieva

P2.02-050 - Weighted Genes Co-expression Network Analysis of Lung Cancers Concerning Patients Overall Survival and Cancer Stage

09:30 - 09:30  |  Presenter: Haolong Qi

P2.02-051 - Bevacizumab Prevents Growth of Established Non-Small Cell Lung Cancer Brain Metastases in Hematogenous Brain Metastasis Model

09:30 - 09:30  |  Presenter: Chinami Masuda

P2.02-052 - A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care

09:30 - 09:30  |  Presenter: James Sun

P2.02-053 - The Prognostic Value of 18 Circulating Markers of Inflammation, Endothelial Activation and
Extracellular Matrix Remodelling in Non-small Cell Lung Cancer Patients

09:30 - 09:30  |  Presenter: Janna Berg

P2.02-054 - Thymidylate Synthase Promotes Epithelial-To-Mesenchymal Transition and Aggressiveness in NSCLC

09:30 - 09:30  |  Presenter: Paolo Ceppi

P2.02-055 - Stratifin Regulates Stabilization of Receptor Tyrosine Kinases via Activation of Ubiquitin-Specific Protease 8 in Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Aya Shiba

P2.02-056 - Regulatory Variants in Cancer-Related Pathway Genes Predict Survival of Patients with Surgically Resected Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Eungbae Lee

P2.02-057 - Expression of MGAT4a and MGAT5 Are Correlated with Poorer Outcome in Advanced Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Yoko Nakanishi

P2.02-058 - Endogenous Arginase 2 as a Biomarker for PEGylated Arginase 1 Treatment in Squamous Cell Lung Carcinoma Xenograft Models

09:30 - 09:30  |  Presenter: Sze Kwan Lam

P2.02-059 - Genomic Mutation Patterns Detected with Cancer Panel Can Predict Postoperative Prognosis in Clinical Stage I Adenocarcinoma

09:30 - 09:30  |  Presenter: Kwanyong Hyun

P2.02-060 - Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Young Wha Koh

P2.02-061 - Two Novel Protein-Based Prognostic Signatures Improve Risk Stratification of Early Lung ADC and SCC Patients

09:30 - 09:30  |  Author(s): E. Martinez-Terroba

P2.02-062 - The MicroRNAs Associated with Recurrence and Metastasis of Stage I Lung Adenocarcinoma

09:30 - 09:30  |  Author(s): H. Dai

P2.02-063 - Oncogenic microRNAs Associated with Poor Prognosis Are Up-Regulated on the Amplicon in Squamous Cell Lung Carcinoma

09:30 - 09:30  |  Presenter: Sana Yokoi

P2.02-064 - A Novel 5-miR Signature Shows Potential as a Diagnostic Tool and as a Predictive Biomarker of Cisplatin Response in NSCLC

09:30 - 09:30  |  Author(s): L. Mac Donagh

P2.02-065 - RanBP9 is a Novel Prognostic and Predictive Biomarker for NSCLC and Affects Cellular Response to Cisplatin and PARP Inhibitors 

09:30 - 09:30  |  Presenter: Anna Tessari

P2.02-066 - Identification of Crucial Gene Targets in the in Situ Environment of Cancer by Google Network Ranking

09:30 - 09:30  |  Presenter: Victor Pontén

P2.02-067 - LKB1 Loss Is Associated with DNA Hypomethylation in Human Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Michael John Koenig

P2.02-068 - BRG1 and p53 Expression in Resected Stage I – III Non-Small Cell Lung Cancer

09:30 - 09:30  |  Author(s): A.A. Elegbede

P2.02-069 - Targeting Neuropilin-1 in NSCLC

09:30 - 09:30  |  Presenter: Martin P Barr

P2.02-070 - C-MET as a Biomarker in Patients with Surgically Resected Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Georgios Tsakonas

P2.02-071 - Prospective Molecular Study of 22 Genes by NGS in Patients with Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Single Institution Experience

09:30 - 09:30  |  Presenter: Valeria Cecilia Denninghoff

P2.02-072 - Reliability of Small Biopsy Samples for Tumor PD-L1 Expression in Non-Small-Cell Lung Cancer

09:30 - 09:30  |  Presenter: Akihito Tsunoda

P2.02-073 - Cytoplasmic Mislocalization of ECT2 Protein Is Associated with Poor Prognosis in Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Zeinab Kosibaty

P2.02-073a - Does the PD-L1 Status and TIL Intensity Change in NSCLC and Syncronous Brain Metastases?

09:30 - 09:30  |  Presenter: Buge Oz

P2.02-073b - Genetic Profile in NSCLC Biopsy Samples. A  Muticenter Local Study

09:30 - 09:30  |  Presenter: Norma Pilnik

P2.03-001 - Survivors and Adverse Events After First-Line Target Therapy for Advanced Non-Small Cell Lung Cancer Patients in Taiwan

09:30 - 09:30  |  Presenter: Lin Zhi Xuan

P2.03-002 - Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations

09:30 - 09:30  |  Presenter: Satoshi Igawa

P2.03-003 - Cost Effectiveness of Gefitinib for Lung Adenocarcinoma Patients with Mutant Epidermal Growth Factor Receptor

09:30 - 09:30  |  Author(s): T. Hsia

P2.03-004 - Recurrent Response to Advanced NSCLC with Erlotinib Developing Central Nervous System Failure during Gefitinib or Icotinib Treatment

09:30 - 09:30  |  Presenter: Di Ma

P2.03-005 - Overall Survival Results from a Prospective, Multicenter Phase II Trial of Low-Dose Erlotinib as Maintenance in NSCLC Harboring EGFR Mutation

09:30 - 09:30  |  Presenter: Satoshi Hirano

P2.03-006 - How Many Years of Life Have We Lost in Brazil Due to the Lack of Access to Anti-EGFR TKIs in the National Public Health System?

09:30 - 09:30  |  Presenter: Pedro Aguiar Jr

P2.03-007 - Loxoprofen Prevents EGFR-TKI-Related Skin Rash in Non-Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

09:30 - 09:30  |  Presenter: Yohei Iimura

P2.03-008 - Phase I/II Study of Intermitted Erlotinib in Combination with Docetaxel in Patients with Recurrent NSCLC with Wild-Type EGFR: WJOG 4708L

09:30 - 09:30  |  Presenter: Tatsuo Kimura

P2.03-009 - Clarification of Mechanisms of Acquired Resistance for Afatinib Using Plasma Samples

09:30 - 09:30  |  Presenter: Tomomi Nakamura

P2.03-010 - Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC

09:30 - 09:30  |  Presenter: Tatsuro Fukuhara

P2.03-011 - Correlation and Problems of Re-Biopsy and Liquid Biopsy for Detecting T790M Mutation

09:30 - 09:30  |  Presenter: Kazutoshi Komiya

P2.03-012 - Characterization of the Efficacies of Osimertinib and Nazartinib against Cells Expressing Epidermal Growth Factor Receptor Mutations

09:30 - 09:30  |  Presenter: Keita Masuzawa

P2.03-013 - Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

09:30 - 09:30  |  Author(s): K. Chen

P2.03-014 - A Phase I Study of Afatinib for Patients Aged 75 or Older with Advanced NSCLC Harboring EGFR Mutations

09:30 - 09:30  |  Author(s): K. Baba

P2.03-015 - Efficacy of EGFR-TKIs for EGFR Mutatnt NSCLC Patients with Central Nervous System Metastases: A Retrospective Analysis

09:30 - 09:30  |  Presenter: Kenichi Koyama

P2.03-016 - Clinical Utility of Liquid Biopsy for Detecting EGFR T790M Mutation Is Very Limited

09:30 - 09:30  |  Presenter: Tomohiro Sakamoto

P2.03-017 - Clinical Features and Treatment with Afatinib in Patients with Squamous Cell Lung Cancer with Sensitive EGFR Mutations

09:30 - 09:30  |  Presenter: Yuri Taniguchi

P2.03-018 - Diagnostic Yield of Fine-Needle Aspiration and Core-Needle Biopsy in Assessment of EGFR and ALK Mutation Status in Non–Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Junghoon Kim

P2.03-019 - Sizing Capillary Electrophoresis with PCR to Detect Various EGFR Exon 19 Deletions in Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Eiji Nakajima

P2.03-020 - Pemetrexed Continuation Maintenance versus Conventional Platinum-based Doublet Chemotherapy in EGFR-negative Lung Adenocarcinoma: Retrospective Analysis

09:30 - 09:30  |  Author(s): I.K. Hwang

P2.03-021 - A Phase I Study Evaluating the Combination of Afatinib, Carboplatin and Pemetrexed after Failure of 1^St Generation EGFR-TKIs

09:30 - 09:30  |  Presenter: Ou Yamaguchi

P2.03-022 - Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC)

09:30 - 09:30  |  Author(s): S. Hong

P2.03-023 - Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic

09:30 - 09:30  |  Presenter: Jana Skrickova

P2.03-024 - Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA

09:30 - 09:30  |  Presenter: Young-Chul Kim

P2.03-025 - Prevalence of EGFR T790M Mutation in NSCLC Patients after Afatinib Failure, and Subsequent Response to Osimertinib

09:30 - 09:30  |  Presenter: Maximilian Johannes Hochmair

P2.03-026 - Managing EGFR T790M Mutation in Advanced Non-Small Cell Lung Cancers in THAILAND

09:30 - 09:30  |  Presenter: Thongbliew - Prempree

P2.03-027 - Comparative Longitudinal Toxicity Analysis of EGFR Mutated NSCLC Treated with Either Pemetrexed Carboplatin or Gefitinib

09:30 - 09:30  |  Presenter: Mansi Sharma

P2.03-028 - Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial

09:30 - 09:30  |  Presenter: Yuankai Shi

P2.03-029 - A Case of a Patient Harboring an EGFR Insertion of Exon 20 and Long Lasting Clinical Response to Afatinib

09:30 - 09:30  |  Author(s): V. Lorandi

P2.03-030 - Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs

09:30 - 09:30  |  Presenter: In Ae Kim

P2.03-031 - Efficacy of Gefitinib and Radiotherapy Combination in Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Elisna Syahruddin

P2.03-032 - Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Hiroyuki Shimada

P2.03-033 - Propensity Score-Adjusted Survival Analysis of Non-Small Cell Lung Cancer Patients with Acquired Resistance to EGFR-TKI

09:30 - 09:30  |  Presenter: Sho Watanabe

P2.03-034 - EGFR Exon 19 Deletion Is Associated with Favorable Overall Survival After First-Line Icotinib Therapy in Advanced NSCLC Patients

09:30 - 09:30  |  Author(s): C. Zhang

P2.03-035 - Osimertinib in Relapsed EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases: Results from the TREM-Study

09:30 - 09:30  |  Presenter: Inger Johanne Zwicky Eide

P2.03-036 - Comparing the Efficacy/Toxicity of Osimertinib and First Line EGFR-TKI by Individual Patient Analysis

09:30 - 09:30  |  Presenter: Shoko Narita

P2.03-037 - Osimertinib in Relapsed EGFR-Mutated, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) Patients: Results from the TREM-Study

09:30 - 09:30  |  Presenter: Inger Johanne Zwicky Eide

P2.03-038 - Early Serum Tumor Markers After 14 Days of Tyrosine Kinase Inhibitor Target Therapy Predicts Outcomes in Patients with Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Kuo-Yang Huang

P2.03-039 - Compassionate Use of Osimertinib: Argentine Experience

09:30 - 09:30  |  Presenter: Jose Nicolas Minatta

P2.03-040 - EGFR T790M Mutation Detection and Osimertinib Treatment Response Evaluation by Liquid Biopsy in Advanced NSCLC Patients

09:30 - 09:30  |  Presenter: Chenguang Li

P2.03-041 - The Concentration of Avitinib in Cerebrospinal Fluid and Its Efficacy and Safety in NSCLC Patients with T790M Mutation

09:30 - 09:30  |  Presenter: Hanping Wang

P2.03-042 - EGFR Mutation and Erlotinib Efficacy in Turkish Oncoregistry

09:30 - 09:30  |  Presenter: Mahmut Gumus

P2.03-043 - A Phase 1b Study of Erlotinib and Momelotinib for TKI-Naïve EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Sukhmani Kaur Padda

P2.03-044 - OSCILLATE - Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFR-T790M Mutation Positive Advanced NSCLC

09:30 - 09:30  |  Presenter: Ben J Solomon

P2.03-045 - Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 8114LTR)

09:30 - 09:30  |  Presenter: Hidetoshi Hayashi

P2.03-046 - Lymhocyte-To-Monocyte Ratio and Mean Platelet Volume as Prognostic Factor in EGFR Mutant NSCLC Treated with EGFR TKI

09:30 - 09:30  |  Presenter: Kousuke Watanabe

P2.03-047 - The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer

09:30 - 09:30  |  Presenter: Songtao Xu

P2.03-048 - Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib

09:30 - 09:30  |  Presenter: Yuki Shinno

P2.03-049 - Pulmonary Adenoid Cystic Carcinoma with EGFR Activating Mutation and Responds Well with Tyrosine Kinase Inhibitor 

09:30 - 09:30  |  Presenter: Jamal Zaini

P2.03-050 - The Efficacy of EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Harboring G719X Mutation

09:30 - 09:30  |  Presenter: Hanping Wang

P2.03-051 - The Impact of EGFR Mutations. Treatment with ITKs in Non Small Cell Lung Cancer Patients

09:30 - 09:30  |  Presenter: Teresa García Manrique

P2.03-052 - Local Ablative Therapy for Oligoprogressive, EGFR-Mutant, Non-Small Cell Lung Cancer (NSCLC) After Treatment with Osimertinib

09:30 - 09:30  |  Author(s): C. Kim

P2.03-053 - A Five-Year Audit of EGFR and ALK Testing at a Tertiary Care Centre in North India: More Sensitive Methods Do Make a Difference!

09:30 - 09:30  |  Presenter: Valliappan Muthu

P2.03-054 - EGFR Mutation with Acquired C-MET Positive Reveals Potential Immunotherapeutic Vulnerabilities

09:30 - 09:30  |  Presenter: Shan Su

P2.03-055 - Comparison of Afatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI

09:30 - 09:30  |  Presenter: Yuichi Sakamori

P2.03-056 - Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 in Slovakian NSCLC Patients - Updated Survival Data

09:30 - 09:30  |  Presenter: Peter Berzinec

P2.03-057 - Effectiveness of Icotinib on Uncommon EGFR Exon 20 Insert Mutations: A763_Y 764insFQEA in Non-Small-Cell Lung Cancer

09:30 - 09:30  |  Author(s): Chunwei Xu

P2.03-058 - Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)

09:30 - 09:30  |  Presenter: James Chih-Hsin Yang

P2.03-058a - T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive NSCLC

09:30 - 09:30  |  Presenter: Takeshi Yoshida

P2.04-001 - BALTIC: A Phase 2, Open-Label Study of Novel Combinations of Immunotherapies or DDR Inhibitors in Platinum-Refractory ED-SCLC

09:30 - 09:30  |  Presenter: Ihor Vynnychenko

P2.04-002 - CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC

09:30 - 09:30  |  Presenter: Luis Paz-Ares

P2.04-003 - Phase II Trial of X-396 (Ensartinib) for Chinese Patients with ALK (+) Non–Small-Cell Lung Cancer Who Progressed on Crizotinib

09:30 - 09:30  |  Presenter: Li Zhang

P2.04-004 - IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC

09:30 - 09:30  |  Presenter: Enriqueta Felip

P2.04-005 - GEOMETRY Mono-1: Phase II, Multicenter Study of MET Inhibitor Capmatinib (INC280) in EGFR Wt, MET-Dysregulated Advanced NSCLC

09:30 - 09:30  |  Presenter: Jürgen Wolf

P2.04-006 - ADAURA: PhIII, Double-Blind, Randomized Study of Osimertinib vs Placebo in EGFR Mutation-Positive NSCLC Post-Tumor Resection

09:30 - 09:30  |  Presenter: Roy S. Herbst

P2.04-007 - KEYNOTE-604: Phase 3 Randomized, Double-Blind Trial of Pembrolizumab/Placebo plus Etoposide/Platinum for Extensive Stage-SCLC

09:30 - 09:30  |  Presenter: Charles M Rudin

P2.04-008 - ATLANTIS: Phase III Study of PM01183 with Doxorubicin vs. CAV or Topotecan in Small-Cell Lung Cancer After Platinum Therapy

09:30 - 09:30  |  Author(s): A. Farago

P2.04-009 - Randomized, Single-Blind Phase 1 Study of Pharmacokinetic Equivalence of ABP 215 Relative to Bevacizumab in Japanese Subjects

09:30 - 09:30  |  Presenter: Valdimir Hanes

P2.04-010 - Afatinib in Combination with Pembrolizumab in Patients with Stage IIIB/IV Squamous Cell Carcinoma (SCC) of the Lung

09:30 - 09:30  |  Presenter: Jonathan W Riess

P2.04-011 - The Using of LungCare Electromagnetic Navigated Bronchoscopy System in Lung Lesions, a New Project in China

09:30 - 09:30  |  Presenter: Baohui Han

P2.04-012 - First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study

09:30 - 09:30  |  Presenter: Yi-Long Wu

P2.04-013 - ElevatION:NSCLC-101 – A Phase 1b Study of PDR001 Combined with Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients

09:30 - 09:30  |  Author(s): Johan F. Vansteenkiste

P2.04-014 - Computing the Impact of Immunotherapy on NSCLC Landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR) 

09:30 - 09:30  |  Author(s): S. Chandwani

P2.05-001 - Does CGA Impact QoL and Overall Survival in NSCLC Patients Treated with SBRT - Results of a Randomized Pilot Study

09:30 - 09:30  |  Presenter: Stefan Starup Jeppesen

P2.05-002 - A Pilot Study on the Safety and the Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumor

09:30 - 09:30  |  Presenter: Takamasa Mitsuyoshi

P2.05-003 - Stage by Stage Comparison of Radiotherapy versus Surgery in NSCLC: The Influence of Prognostic Factors on Survival Outcome

09:30 - 09:30  |  Presenter: Sara Moore

P2.05-004 - Radiotherapy Patterns of Care for Stage I and II Non-small-cell Lung Cancer in Sydney, Australia

09:30 - 09:30  |  Presenter: Andrew Duy Duc Nguyen

P2.05-005 - Proton Beam Therapy for Early Stage Lung Cancer: A Multi-Institutional Retrospective Study in Japan

09:30 - 09:30  |  Presenter: Kayoko Ohnishi

P2.05-006 - Credentialing of Radiotherapy Centres in Australasia for a Phase III Clinical Trial on SABR (TROG 09.02 CHISEL)

09:30 - 09:30  |  Author(s): T. Kron

P2.05-007 - Sterotactic-Body-Radiotherapy for Early-Lung Cancer: Is FDG-PET/TC a Predictor of Outcome?

09:30 - 09:30  |  Author(s): N. Farré

P2.05-008 - Stereotactic Body Radiotherapy (SBRT) for Early Stage I Lung Cancer: A Review from an Oncology Center in Hong Kong

09:30 - 09:30  |  Presenter: Lim Mei Ying

P2.05-009 - Outcome of Stereotactic Body Radiotherapy for Clinical Stage I Non Small Cell Lung Cancer and CT Findings: Comparison with Surgical Resection

09:30 - 09:30  |  Presenter: Yuho Maki

P2.05-010 - Changes between Pre- and Post-Operative AICS (Lung) in NSCLC Patients: Predictability of High-Risk Cases with Recurrence

09:30 - 09:30  |  Presenter: Masahiko Higashiyama

P2.05-011 - Segmentectomy versus Wedge Resection in Patients with Clinical Stage I Non-Small Cell Lung Cancer Who Were Unfit for Lobectomy

09:30 - 09:30  |  Presenter: Yasuhiro Tsutani

P2.05-012 - Prognostic Factors for Surgically Resected Non-Small Cell Lung Cancer with Cavity Formation 

09:30 - 09:30  |  Presenter: Shunsuke Shigefuku

P2.05-013 - The Result of Preoperative Lipiodol Markings for 121 Small Pulmonary Nodules in 115 Patients

09:30 - 09:30  |  Presenter: Hirofumi Suzuki

P2.05-014 - Factors Associated with Recovery Time to Predicted FEV1 in Non-Small-Cell Lung Cancer Patients after Lobectomy

09:30 - 09:30  |  Author(s): H.W. Kim

P2.05-015 - Wedge Resection Is Enough for Curing GGO Patients with Minimally Invasive Adenocarcinoma (MIA) of the Lung?

09:30 - 09:30  |  Presenter: Jun Zhang

P2.05-016 - Clinical Importance and Application of New T Descriptors in the 8th TNM Classification for Pathological T0-1 Lung Adenocarcinoma

09:30 - 09:30  |  Presenter: Masayuki Nakao

P2.05-017 - Prognostic Impact of the Clinical T Descriptor in the Eighth Edition of the TNM Staging System of Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Tatsuro Okamoto

P2.05-018 - Video-Assisted Thoracoscopic Surgery vs Thoracotomy for Early-Stage Non-Small Cell Lung Cancer: Short-Term Outcomes of a Randomized Trial

09:30 - 09:30  |  Presenter: Dongrong Situ

P2.05-019 - Overall Survival (OS) of Pathological T1N0 Non-Small Cell Lung Cancer (NSCLC) After Resection.

09:30 - 09:30  |  Presenter: Etienne Bourdages-Pageau

P2.05-020 - Prognostic Factors in Patients with Completely Resected Subsolid Node-Negative Lung Adenocarcinoma of 3cm or Smaller

09:30 - 09:30  |  Presenter: Jung-Jyh Hung

P2.05-021 - Occult Nodal Metastasis Following Lobectomy for Clinical Stage I Lung Adenocarcinoma: Implications for Sublobar Resection

09:30 - 09:30  |  Presenter: Yusuke Takahashi

P2.06-001 - Circulating Cotinine Concentrations, Self-Reported Smoking, and Lung Cancer Risk in the Lung Cancer Cohort Consortium (LC3)

09:30 - 09:30  |  Presenter: Tricia L. Larose

P2.06-002 - Tobacco Use and Prevalence of Head and Neck Cancers among Malayali Tribes, Yelagiri Hills, Tamil Nadu, India

09:30 - 09:30  |  Presenter: Delfin Lovelina Francis

P2.06-003 - Retrospective Study of Cerebral Thromboembolism Occurring before and after Detection of Lung Cancer (Trousseau Syndrome)

09:30 - 09:30  |  Presenter: Kinnosuke Matsumoto

P2.06-004 - Role of Polymorphic Variants of BER and DSBR Pathway Genes in Modulating Lung Cancer Susceptibility and Prognosis of North Indian Population

09:30 - 09:30  |  Presenter: Amrita Singh

P2.06-005 - An Exploration of Attitudes and Barriers to Uptake of Lung Cancer Screening in at Risk Adults in the United Kingdom

09:30 - 09:30  |  Author(s): E.L. O'Dowd

P2.06-006 - Screening Values of CEA and Cyfra 21-1 for Lung Cancer in Combination with Low Dose CT (LDCT) in High-Risk Populations

09:30 - 09:30  |  Presenter: Natthaya Triphuridet

P2.06-007 - Demographic Characteristics of Lung Cancer and Association with Wood Smoke in Mexican Population

09:30 - 09:30  |  Presenter: Jeronimo Rafael Rodriguez-Cid

P2.06-008 - Diagnosis of Incidental Disease in Medicaid Recipients During Lung Cancer Screening

09:30 - 09:30  |  Presenter: Marisa Bittoni

P2.06-009 - Trace Elements Affect Lung Cancer Subtypes

09:30 - 09:30  |  Presenter: Ryosuke Chiba

P2.06-010 - Association of Vitamin D Receptor BsmI Polymorphism with Lung Cancer Risk: Evidence from a Meta-Analysis

09:30 - 09:30  |  Author(s): A. Zhong

P2.06-011 - Assessing and Addressing Knowledge Gaps to Improve Lung Cancer Screening Rates

09:30 - 09:30  |  Author(s): G. Westphal

P2.07-001 - Clinicopathological Characteristics of NSCLC Patients with Nivolumab-Induced Pneumonitis

09:30 - 09:30  |  Presenter: Nobuyuki Koyama

P2.07-002 - Drug-Related Pneumonitis in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Commercial PD-1 Inhibitors

09:30 - 09:30  |  Presenter: Mizuki Nishino

P2.07-003 - Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Hironori Yoshida

P2.07-004 - Immune-Related Adverse Events (irAEs) of Nivolumab Predicts Clinical Benefit in Advanced Lung Cancer Patients

09:30 - 09:30  |  Presenter: Yukihiro Toi

P2.07-005 - Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

09:30 - 09:30  |  Author(s): C. Henon

P2.07-006 - Irinotecan Augmented Anti-Tumor Activity of Anti-PD-L1 through Enhancing CD8 Proliferation Regardless of Its Hematotoxicity

09:30 - 09:30  |  Presenter: Toshiki Iwai

P2.07-007 - Retrospective Analysis of Antitumor Effects and Biomarkers of Nivolumab in NSCLC Patients with EGFR Mutations

09:30 - 09:30  |  Presenter: Satoshi Watanabe

P2.07-008 - Does PD-L1 Expression of the Archive Surgical Specimen of Primary Tumor Predict the Sensitivity of Recurrence to Nivolumab in Patients with NSCLC?

09:30 - 09:30  |  Presenter: Yuki Shiina

P2.07-009 - Monitoring Nivolumab Binding as a Method to Clarify the Residual Therapeutic Effects in Previously Treated Lung Cancer Patients

09:30 - 09:30  |  Presenter: Akio Osa

P2.07-010 - Impact of Clinicopathological Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients with Previously Treated Non-Small Cell Lung Cancer

09:30 - 09:30  |  Presenter: Tao Jiang

P2.07-011 - Long Follow up from Phase I Study of Nivolumab and Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

09:30 - 09:30  |  Presenter: Shintaro Kanda

P2.07-012 - Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC) 

09:30 - 09:30  |  Author(s): S. Schmid

P2.07-013 - Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer with Preexisting Interstitial Lung Disease

09:30 - 09:30  |  Presenter: Osamu Kanai

P2.07-014 - Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer

09:30 - 09:30  |  Presenter: Hironori Ashinuma

P2.07-015 - Reviving Chemotherapy Sensitivity after Anti-CCR4 mAb (Mogamulizumab) Treatment in Lung Cancer Patients

09:30 - 09:30  |  Presenter: Koji Kurose

P2.07-016 - Inmunotherapy:  Which Is More Important,  Choosing Patients Who Will Respond or Identifying Those Who Will Die Early?

09:30 - 09:30  |  Presenter: Inmaculada Ramos García

P2.07-017 - Association between Thyroid Dysfunction and Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Received Nivolumab

09:30 - 09:30  |  Presenter: Tomoko Funazo

P2.07-018 - Correlation of Clinical Response and XAGE1 Immunity in Lung Adenocarcinoma